Title	Endothelial dysfunction: A strategic target in the treatment of hypertension?
Author(s)	Tang, EHC; Vanhoutte, PM
Citation	Pflugers Archiv European Journal Of Physiology, 2010, v. 459 n. 6, p. 995-1004
Issued Date	2010
URL	http://hdl.handle.net/10722/139591
Rights	The original publication is available at www.springerlink.com

Pflugers Arch - Eur J Physiol
DOI 10.1007/s00424-010-0786-4

CARDIOVASCULAR PHYSIOLOGY

Endothelial dysfunction: a strategic target in the treatment of hypertension?

Eva H. C. Tang · Paul M. Vanhoutte

Received: 14 December 2009 / Revised: 6 January 2010 / Accepted: 8 January 2010

Abstract Endothelial dysfunction is a common feature of hypertension, and it results from the imbalanced release of endothelium-derived relaxing factors (EDRFs; in particular, nitric oxide) and endothelium-derived contracting factors (EDCFs; angiotensin II, endothelins, uridine adenosine tetraphosphate, and cyclooxygenase-derived EDCFs). Thus, drugs that increase EDRFs (using direct nitric oxide releasing compounds, tetrahydrobiopterin, or L-arginine supplementation) or decrease EDCF release or actions (using cyclooxygenase inhibitor or thromboxane A2/prostanoid receptor antagonists) would prevent the dysfunction. Many conventional antihypertensive drugs, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and third-generation β-blockers, possess the ability to reverse endothelial dysfunction. Their use is attractive, as they can address arterial blood pressure and vascular tone simultaneously. The severity of endothelial dysfunction correlates with the development of coronary artery disease and predicts future cardiovascular events. Thus, endothelial dysfunction needs to be considered as a strategic target in the treatment of hypertension.

E. H. C. Tang (✉)
Division of Cardiovascular Medicine,
Brigham and Women's Hospital, Harvard Medical School,
77 Ave Louis Pasteur, NRB741,
Boston, MA 02115, USA
e-mail: htang@rics.bwh.harvard.edu

P. M. Vanhoutte
Department Pharmacology and Pharmacy,
Li Ka Shing Faculty of Medicine, University of Hong Kong,
Hong Kong, China

P. M. Vanhoutte
Department BIN Fusion Technology,
Chonbuk National University,
Jeonju, Korea

Keywords Endothelium · Prostaglandin · Contraction · Free radical · Hypertensive rats

Introduction

The endothelium, the thin layer of cells that lines the interior surface of blood vessels, can be activated by various chemical and physical stimuli to simultaneously release endothelium-derived relaxing (EDRFs) and contracting (EDCFs) factors. EDRFs and EDCFs act as acute functional antagonists and exert opposing effects on the underlying vascular smooth muscles to control their tone (Fig. 1). When endothelial cells are exposed to a chronic elevation in arterial blood pressure, they age prematurely, their turnover is accelerated, and they are replaced by regenerated endothelial cells [1, 2]. However, the regenerated endothelium has an impaired ability to release EDRFs (endothelial dysfunction)—in particular, nitric oxide (NO) [3, 4]—which results in the weakening of the inhibitory brake to oppose the action of EDCFs, with ensuing prominence of endothelium-dependent contractions (constrictions) [5]. Endothelial dysfunction can trigger a chain of undesired responses, including increases in platelet aggregation, expression of adhesion molecules, and vascular smooth muscle growth [1, 6]. Thus, a vicious cycle is established, ultimately contributing to thrombosis, inflammation, vascular remodeling, and atherosclerosis.

Endothelial dysfunction has been demonstrated both in resistance arteries and conduit arteries of several hypertensive animals, including the spontaneously hypertensive rat (SHR) [7–9], the two-kidney one-clip model [10, 11], deoxycorticosterone acetate salt-treated animals [12], and the Dahl salt-sensitive rat [13, 14]. Evidence of endothelial dysfunction in human hypertension has been characterized



Q2 **Fig. 1** In healthy arteries, a normal vascular tone is maintained by the balanced release of EDRF and EDCF. This balance is tipped in hypertensive arteries with an increase in the release of EDCF and a decrease in the release of EDRF, favoring contractions. *EC* endothelial cell, *SMC* smooth muscle cell

by decreased forearm blood flow responses to endothelium-dependent vasodilator agonists, such as acetylcholine and bradykinin [15, 16], or by an increase in vasoconstrictor response to locally administered nitric oxide synthase inhibitors [17].

Endothelium-derived relaxing factors

The endothelium produces a range of EDRFs, the most significant and well-characterized of which is NO. But prostacyclin and endothelium-derived hyperpolarizing factors are also important endothelium-derived vasodilator signals, with the latter prominently contributing to endothelium-dependent relaxations in resistance arteries [18]. The majority of studies on endothelial dysfunction have concentrated on the mechanisms underlying the decreased bioavailability of NO. This decrease may result from a decrease in NO production, from a decrease in activation of guanylyl cyclase, and/or an increase in NO degradation (Fig. 2). A decrease in NO production may result from a deficiency in substrates and cofactors for NO sythases (NOS), such as L-arginine or tetrahydrobiopterin (BH_4) [13, 19]; from a decreased expression and presence of endothelial NOS (eNOS) [20]; from a decreased activation of NOS, such as phosphorylation of the enzyme or interactions with proteins (e.g., heat shock protein 90 or calmodulin) [20]; or from an increased presence of endogenous inhibitors of NOS, asymmetric dimethyl arginine in particular [21] (Fig. 2). An increase in NO degradation can result from the binding of NO to molecules such as hemoglobin and albumin, or from increased inactivation of NO by its interaction with superoxide anions [22]—a reaction which leads to the production of peroxynitrite, a toxic vascular oxidant that further contributes to vasoconstriction and vascular injury (Fig. 2). Animal and clinical studies indicate that hypertension is associated with an increase in the production of reactive oxygen species (ROS), together with a decreased level of endogenous antioxidants [23–25]. The ability of vitamin C to restore NO production and improve endothelial function in essential hypertensive patients suggests a role of oxidative stress in endothelial dysfunction in humans [25].

Endothelium-derived contracting factors

The endothelial cells can produce several EDCFs, including angiontensin II, endothelin-1, dinucleotide uridine adenosine tetrahosphate (UP_4A), cyclooxygenase (COX)-derived prostanoids, and ROS [5, 26]. When these endothelium-derived vasoconstrictors are overproduced, such as in hypertension or diabetes, they oppose the vasodilator effects of the EDRFs, exacerbating endothelial dysfunction.

Angiotensin II

Angiotensin I is metabolized into angiotensin II by endothelial angiotensin-converting enzyme (ACE). Angiotensin II can activate angiotensin receptors and trigger an increase in cytosolic calcium to mediate contractions [27]. In addition to causing vasoconstriction, angiotensin II can enhance the production of ROS—predominately through the activation of membrane-bound nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate oxidases—and thus, impairs NO bioavailability [28]. Furthermore, angiotensin II can directly stimulate the production and release of endothelin-1 and thus aggravate endothelial dysfunction [29].

Endothelin-1

There are three isoforms of endothelin (identified as ET-1, ET-2, and ET-3) that activate two subtypes of receptors (ET_A and ET_B) [30]. ET_A and ET_B receptors are found in the vascular smooth muscle and are coupled to a G_q-protein that leads to IP_3 formation [30]. IP_3 stimulates calcium release



Fig. 2 Decreased bioavailability of nitric oxide may result from a decrease in NO production, an increase in NO degradation, or a decrease in the activation of guanylyl cyclase. Decreased NO production may result from deficiency in substrates and cofactors for nitric oxide synthase (NOS), decreased expression of NOS, decreased activation of NOS, or an increase in endogenous inhibitors of NOS. An increase in NO degradation can result from the binding of NO to molecules such as superoxide anions, hemoglobin, and albumin. *ADMA* asymmetric dimethyl arginine, *BH_4* tetrahydrobiopterin, *EC* endothelial cell, *hsp90* heat shock protein 90, *NOS* nitric oxide synthase, *O_2*, *ONOO* peroxynitrite, *P* phosphorylation, *SMC* smooth muscle cell

from the sarcoplasmic reticulum, which contributes to the contraction of the vascular smooth muscle [30]. Because of its powerful vasoconstrictor properties, and the retention of sodium that it causes, endothelin-1 (the main isoform produced by endothelial cells) increases arterial blood pressure. ET_B receptors are primarily located on endothelial cells, and when stimulated, they increase the release of NO and augment natriuresis and diuresis, thus lowering blood pressure [31]. The distribution of endothelin receptors on endothelial and smooth muscle cells helps to explain the phenomenon that systemic administration of endothelin-1 causes an initial transient vasodilatation (endothelial ET_B activation) and hypotension, followed by prolonged vasoconstriction and hypertension (ET_A and ET_B activation of vascular smooth muscle). Endothelin-1 can also induce the secondary release of cyclooxygenase-dependent EDCFs (presumably endoperoxides and thromboxane A_2) that cause the activation of thromboxane A2/prostanoid (TP) receptors of vascular smooth muscle [32–34].

Uridine adenosine tetraphosphate

UP_4A is a non-peptidic dinucleotide endothelium-derived vasoconstrictor that is assumed to play a role in the regulation of vascular tone [35]. UP_4A possesses both purine and pyrimidine moieties, and the contraction that it causes is mediated predominately through P2X1, and probably also through P2Y2 and P2Y4 purinoceptors. UP_4A is released from the endothelium in response to acetylcholine, endothelin-1, the calcium ionophore A23187, adenosine, and uridine triphosphate [35]. The role of UP_4A in the pathogenesis of hypertension is yet to be determined.

COX-derived EDCFs

The importance of COX-derived vasoconstrictor prostanoids has gained significant recognition in the past decade. The production of endothelium-derived prostanoids is augmented in arteries with regenerated endothelium [36, 37], and in normotensive aging and hypertensive arteries [5, 7, 9, 38]. The endothelium of the renal arteries of healthy rats also releases EDCF, suggesting that it may play a role in the regulation of basal tone in this artery, and not only during agonist-induced stimulated release [39, 40]. Studies in humans show that the acetylcholine-induced vasodilatation is diminished in conductance and resistance vessels of patients with hypertension. In these hypertensive patients, intra-arterial administration of the COX inhibitor indomethacin improved the vasodilator response to acetylcholine [41, 42], suggesting that the production of COX-derived EDCF contributes to the onset of endothelial dysfunction in human hypertension.

Mechanisms underlying the production of COX-derived EDCFs

In brief, the chain of events leading to endothelium-dependent contractions requires an abnormal increase in

intracellular calcium in the endothelial cells [5, 26]. The rise in calcium activates phospholipase A_2 to release arachidonic acid from the cell membrane phospholipids. Then COX breaks down arachidonic acid to form prostanoids that activate TP receptors located in the vascular smooth muscle, resulting in contraction [5, 26]. During the production of prostanoids, COX simultaneously produces ROS, which can subsequently stimulate COX within the smooth muscle and produce more prostanoids [5, 26], thus amplifying the TP receptor-mediated response (Fig. 3).

Calcium overload

An abnormal, high accumulation of intracellular calcium in endothelial cells is critical and triggers the production of COX-derived EDCFs [43] (Fig. 3). Stimulation with acetylcholine results in calcium overload in the aortic endothelial cells of SHR, but not in normotensive Wistar Kyoto rats (WKY), signifying dysfunction of calcium handling in the hypertensive strain [43]. When calcium overload is mimicked in WKY arteries using calcium-increasing agents (such as the calcium ionophore A23187 or cyclopiazonic acid), endothelium-dependent contractions are evoked despite the normal arterial blood pressure of the animals. Nonetheless, the amplitude of the contraction remains larger in SHR than in WKY [43]. This is explained best by the increased expression of COX and prostanoid synthases, a greater release of prostanoids, as well as a hyper-responsiveness of the TP receptors in the aortas of SHR than in that of WKY [5, 44–46]. Hence, all these downstream modifications are not a prerequisite for the development of endothelium-dependent contractions, but their presence amplifies the response.

COX activity

The activity of COX is required for the generation of vasoconstrictor prostanoids. Two isoforms of COX, a constitutive form (COX1) and an inducible form (COX2), have been cloned and characterized [47]. Yet COX1—termed as the constitutive isoform—can be over-expressed under certain conditions, such as increases in shear stress [47]. Inflammation is the most common cause for the up-regulation of COX2 [47]. Multiple studies using arteries from mice and rats have confirmed that COX1 is the primary isoform involved in endothelium-dependent contractions. For example, endothelium-dependent contractions are abolished by selective COX1 inhibitors, but are relatively insensitive to selective COX2 inhibitors [9, 48]. Furthermore, endothelium-dependent contractions occur in the aortas of wild-type and $COX2^{-/-}$ knockout mice, but not in those of $COX1^{-/-}$ knockout mice [49]. Later studies using hamster aortas [50] and aging rats [51], however, showed that COX2 can contribute equally to the contraction when present or induced in the endothelial cells.



Fig. 3 Endothelium-dependent contraction has two components: the generation of prostaglandins and ROS. A rise in calcium activates phospholipase A_2 (PLA_2) to release arachidonic acid, which is subsequently metabolized by cyclooxygenase (COX) to form endoperoxides and various prostaglandins that activate TP receptors located at the vascular smooth muscle. COX also produces ROS, which diffuses or possibly transmigrates via gap junctions and stimulates COX within the smooth muscle, producing more prostanoids and amplifying TP receptor-mediated contractions. *ADP* adenosine diphosphate, *m* muscarinic receptors, *P* purinergic receptors, PGE_2 prostaglandin E_2, $PGF_{2\alpha}$ prostaglandin $F_{2\alpha}$; PGI_2 prostacyclin, *ROS* reactive oxygen species, TXA_2 thromboxane A_2

Production of prostanoids

The immediate products of COX are the endoperoxides, which themselves function as vasoconstrictors by binding to TP receptors [45]. Endoperoxides are further transformed into prostacyclin, thromboxane A_2, prostaglandin E_2, prostaglandin $F_{2\alpha}$, and prostaglandin D_2 by their respective prostanoid synthases (Fig. 3). Prostacyclin synthase is by far the most abundant prostanoid synthase expressed in the endothelium [52]. Its expression is augmented in the aorta of SHR compared with that of WKY [52, 53], suggesting that chronic hypertension induces the protein. In line with this observation, there is an exaggerated release of prostacyclin in the aorta of the hypertensive rat [46, 54, 55]. Since this classical vasodilator prostanoid does not mediate relaxation in this artery, it instead evokes contraction through activation of TP receptors at high concentrations [44]. In response to acetylcholine, prostacyclin and endoperoxides are the key mediators of endothelium-dependent contractions in the rat aorta [5, 44]. Whether or not prostacyclin plays a detrimental role as EDCF in other animal models or in humans remains to be demonstrated.

Under certain pathological conditions involving enhanced oxidative stress, ROS interacts with NO to form peroxynitrite [22], which can significantly inhibit the activity of prostacyclin synthase by tyrosine nitration of the enzyme [56, 57]. Under such circumstances, there is a marked compensatory production of prostaglandin E_2 and prostaglandin $F_{2\alpha}$, leading to greater importance of these two prostanoids [46, 56, 58]. In the hamster aorta and in human renal arteries, there is a high expression of COX2 and a prominent release of prostaglandin $F_{2\alpha}$, indicating the importance of this prostanoid as the EDCF in these arteries [50]. Likewise, prostaglandin $F_{2\alpha}$ is the major EDCF released from re-endothelized femoral rat arteries [36].

When endothelium-dependent contractions are evoked by the calcium ionophore A23187 or adenosine diphosphate (ADP) in the aorta of SHR, the response is partly sensitive to inhibitors of thromboxane synthase [54, 55, 59], implying the involvement of thromboxane A_2. The mRNA expression of thromboxane synthase is enhanced in the aorta of SHR compared to WKY [52]. Direct chemical detection with immunoassays has revealed that A23187 and ADP stimulate the release of thromboxane A_2 and endoperoxides [46, 54, 55], suggesting that these prostanoids are the key mediators of endothelium-dependent contraction during exposure to these agonists.

On the whole, there is a marked heterogeneity in the formation of EDCF. The precise chemical identity of EDCF varies depending on the stimulus, the vascular bed, the age, and the physiopathological condition of the donor animal. Thus, prostacyclin, thromboxane A_2, prostaglandin E_2, prostaglandin $F_{2\alpha}$, and ROS all have been proposed as COX-derived EDCF. It is important to keep in mind that endothelium-dependent contractions are unlikely to be due a single substance, but rather likely are evoked by a mixture of these endothelium-derived products (Fig. 3).

The involvement of TP receptors

Prostanoid receptors are classified into five discrete types based on their sensitivity to the five naturally occurring prostanoids: prostacyclin I_2, thromboxane A_2, prostaglandin D_2, prostaglandin E_2, and prostaglandin $F_{2\alpha}$. They are termed P receptors—IP, TP, DP, EP, and FP—with the preceding letter indicating the prostanoid to which they are the most sensitive. The effectiveness of TP receptor inhibitors in abolishing endothelium-dependent contractions pinpoints the involvement of this prostanoid receptor subtype in the response [48, 60–62]. Although thromboxane A_2 is the most potent agonist towards TP receptors, it is not its exclusive ligand. All other prostanoids can bind to TP receptors and mediate contraction, but with varying potency. The mRNA and protein expression of TP receptors does not differ in the aortas of WKY and SHR, indicating that their expression level is not altered by the hypertensive process [52, 63]. However, the vascular smooth muscle of the SHR aorta exhibits a greater responsiveness than that of the WKY to the constrictor effect of endoperoxides acting at TP receptors [45]. An involvement of other prostanoid receptors in endothelium-dependent contractions has been suggested [63–65], but non-TP receptor endothelium-dependent component appears to constitute a small part of the full response.

A separate ROS component

During the production of prostanoids by endothelial COX, ROS are formed simultaneously. These COX-derived ROS can act as vasoconstrictors [43, 62]. Thus, COX-derived EDCF-mediated contractions can be attributed to two components—prostanoids or ROS [5] (Fig. 3). The possible existence of a separate ROS component in endothelium-dependent contractions is strengthened by the following observations: First, that the generation of ROS by xanthine plus xanthine oxidase in the extracellular bathing fluid evokes a contraction in the aorta without endothelium that requires the activity of COX and stimulation of TP receptors [62, 66], suggesting that endothelium-derived ROS could stimulate COX in the vascular smooth muscle with resulting prostanoid production, causing more TP receptor-mediated contraction. Second, the direct application of hydrogen peroxide, but not that of superoxide anions or hydroxyl radicals, triggers contractions in the rat

aorta that are sensitive to cyclooxygenase inhibitors and TP receptor antagonists [66–69], suggesting that hydrogen peroxide is the mediator responsible for the ROS component of endothelium-dependent contraction. Myoendothelial gap junctions may facilitate the transfer of ROS from endothelial cells to smooth muscle cells [70]. In the aorta of the SHR, both the prostanoid and ROS component appear to contribute equally to the final endothelium-dependent contractions, as antioxidants only partly reduce the response [62]. By contrast, in the canine basilar artery, endothelium-dependent contractions are fully prevented by superoxide dismutase plus catalase [71], indicating that the response is dominated by the endothelial ROS component.

Therapeutic interventions to improve endothelial function in hypertension

Considering the marked endothelial dysfunction in hypertension and since its severity correlates with the development of coronary artery disease and predicts future cardiovascular events [72], this dysfunction has to be considered as a central target in the treatment of hypertension. Theoretically, drugs targeted to increase the release of EDRF (and in particular, NO), and drugs that decrease the production or action of EDCF, should reduce endothelial dysfunction.

Improving NO production

Direct NO releasing compounds, such as nitroglycerin, are effective vasodilators. However, continuous administration comprises a clinical problem due to the desensitization of the target enzyme guanylyl cyclase, leading to cross-tolerance to other endothelium-dependent vasodilators [73]. Other concerns involve the ability of nitroglycerin to increase ROS indirectly [74].

Acute supplementation with BH_4, an essential cofactor of NOS, improves endothelial dysfunction by increasing NO and reducing ROS in many experimental animal studies [75]. But a clinical trial of the effects of BH_4 on arterial blood pressure in subjects with poorly controlled systemic hypertension has been terminated for lack of significant beneficial effect [76]. By contrast, positive results have been reported with the use of BH_4 to treat endothelial dysfunction in patients with sickle-cell disease [76]. The dissimilar results in these clinical trials highlight the importance of fully addressing basic questions about the mechanism of endothelial regulation that will be critical in the design of BH_4-based therapies.

Endogenous NO formation is largely dependent on the extracellular concentrations of its substrate, L-arginine. Supplementation of L-arginine leads to a measurable decline in blood pressure and improved endothelial functions in experimental animals and in hypertensive patients [77, 78]. Most L-arginine studies to date have used high daily doses, due to the pharmacokinetics of oral L-arginine, which reaches its highest concentration in the blood within an hour and then diminishes quickly [77]. The use of sustained-release L-arginine products in hypertensive patients shows promising signs of improving endothelial function [79].

When arteries are exposed to NO, whether released from the endothelial cells or added exogenously, this causes a long-term inhibition of endothelium-dependent contractions [80–83]. This implies a suppressed occurrence of EDCF-mediated contractions under conditions where there is an adequate release of NO. Thus, NO-enhancing agents not only will enhance vasodilatation, but also will hamper the occurrence of endothelium-dependent contractions.

Reducing arterial blood pressure

Antihypertensive treatments—such as ACE inhibitors, calcium channel blockers, and third generation β-blockers—reverse endothelial dysfunction in experimental animals and in hypertensive patients [84, 85]. Several effects of ACE inhibitors enhance NO release and bioactivity, including preventing the breakdown of endogenous bradykinin (a potent NO releaser) [85]. ACE inhibitors also protect NO bioavailability [85]. The beneficial effect of calcium channel blockers on endothelial dysfunction can be attributed to their ability to reduce calcium entry through voltage-dependent channels of the vascular muscle cells, thereby dilating large conduit and resistance arteries [86]. In addition, drugs such as amlodipine activate eNOS to release more NO [87, 88]. Other calcium channel blockers, such as lacidipine, possess antioxidant properties [89], while third-generation β-blockers such as carvedilol and nebivolol, in addition to their adrenergic blocking characteristics, substantially improve endothelial dysfunction through their strong stimulatory effect on the activity of endothelial NOS and their antioxidative properties [90]. Blood pressure reduction per se does not guarantee improvement in endothelial dysfunction. Other antihypertensive drugs, such as conventional β-adrenergic blockers, reduce arterial blood pressure but fail to restore normal endothelial function [85].

Preventing EDCF-mediated responses

Because prostacyclin is one of the main mediators of endothelium-dependent contractions in the response of acetylcholine, inhibition of its production may result in the improvement of endothelial function. But prostacyclin also is beneficial to the vascular system because of

its ability to prevent aggregation of platelets and avoid thrombosis [91]. In addition, inhibition of prostacyclin synthase results in the build-up of endoperoxides (which by themselves activate TP receptors) and the shunting of the latter to other synthases, which produce more potent vasoconstrictor prostanoids [46, 54, 55]. Therefore, selective inhibition of prostacyclin synthase would not reduce the occurrence of unwanted endothelium-dependent contractions, but rather would result in amplified worsening of the vascular complications. In the SHR aorta, thromboxane A_2, and endoperoxides are the main EDCF in response to A23187 and adenosine diphosphate [44, 54, 55]. In the aorta of the hamster, in response to acetylcholine, the main EDCF is prostaglandin $F_{2\alpha}$ [50]. Thus, the contribution of various prostaglandins released during endothelium-dependent contractions varies depending on the stimulus, the artery, the species, and the disease state of the donor. It therefore appears more desirable to design drugs that target either upstream or downstream of the EDCF cascade, rather than individual prostanoid synthases, to alleviate EDCF-mediated endothelial dysfunction.

Depending on the availability of the enzyme, both COX1 and COX2 can contribute to endothelium-dependent contractions. Thus, the use of selective drugs targeting a specific isoform of COX is not the rationale of choice to inhibit endothelium-dependent contractions in hypertension. Moreover, the use of non-selective COX inhibitors are linked with multiple adverse effects, including peptic ulceration and dyspepsia, while selective COX-2 inhibition increases the risk of myocardial infarction, thrombosis, and stroke [92].

EDCFs ultimately converge to activate TP receptors [48, 60–62]. Although other prostanoid receptors may contribute [63–65], it seems—at least from data obtained in animal studies—that TP receptors are the dominant receptor subtype involved. The TP receptor blocker terutroban improves endothelial function in patients with coronary disease [93], which illustrates the role of vasoconstrictor prostanoids in human endothelial dysfunction. Thus, selective TP receptor antagonists may be the most logical therapeutic tools to intervene with endothelium-dependent contractions in hypertension. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids function as endogenous TP-receptor antagonists and induce vasodilatation [94], suggesting their use as novel TP receptor inhibitors. Synthetic TP receptor blockers (such as terutroban) effectively prevent endothelium-dependent contraction in numerous hypertensive experimental animal models [7, 48, 51, 60–62]. The prospective use of TP-receptor antagonists in correcting the consequences of the imbalanced release of endothelium-derived vasoactive substances in hypertensive patients deserves further exploration.

Conclusion

The endothelium is one of the major target organs that are damaged by high blood pressure. Chronic elevation in blood pressure accelerates the turnover of endothelial cells, causing them to age prematurely. The regenerated endothelium has an impaired ability to release EDRF and favors the occurrence of endothelium-dependent contractions. Endothelial dysfunction triggers a chain of undesired responses, including increased platelet aggregation, expression of adhesion molecules, and vascular muscle growth—ultimately leading to thrombosis, inflammation, vascular remodeling, and atherosclerosis. Endothelial dysfunction therefore should be considered as a central target in the treatment of hypertension. Mechanisms that increase EDRF or decrease the release/bioavailability action of EDCF are promising drug targets to mitigate the damage caused by endothelial dysfunction.

References

1. Félétou M, Vanhoutte PM (2006) Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291:H985–H1002
2. Susic D (1997) Hypertension, aging, and atherosclerosis. The endothelial interface. Med Clin North Am 81:1231–1240
3. Flavahan NA, Vanhoutte PM (1990) G-proteins and endothelial responses. Blood Vessels 27:218–229
4. Shibano T, Codina J, Birnbaumer L, Vanhoutte PM (1994) Pertussis toxin-sensitive G proteins in regenerated endothelial cells of porcine coronary artery. Am J Physiol 267:H979–H981
5. Tang EH, Vanhoutte PM (2009) Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 122:140–149
6. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M (2009) Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196:193–222
7. Michel FS, Man GS, Man RY, Vanhoutte PM (2008) Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat. Br J Pharmacol 155:217–226
8. Sekiguchi F, Nakahira T, Kawata K, Sunano S (2002) Responses to endothelium-derived factors and their interaction in mesenteric arteries from Wistar Kyoto and stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 29:1066–1074
9. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Félétou M (2004) Endothelium-dependent contractions to acetylcholine, ATP and the calcium ionophore A 23187 in aortas from spontaneously hypertensive and normotensive rats. Fundam Clin Pharmacol 18:321–326
10. Lee J, Choi KC, Yeum CH, Kim W, Yoo K, Park JW, Yoon PJ (1995) Impairment of endothelium-dependent vasorelaxation in chronic two-kidney, one-clip hypertensive rats. Nephrol Dial Transplant 10:619–623
11. Stankevicius E, Martinez AC, Mulvany MJ, Simonsen U (2002) Blunted acetylcholine relaxation and nitric oxide release in arteries from renal hypertensive rats. J Hypertens 20:1571–1579
12. Cordellini S (1999) Endothelial dysfunction in DOCA-salt hypertension: possible involvement of prostaglandin endoperoxides. Gen Pharmacol 32:315–320

13. Zhou MS, Kosaka H, Tian RX, Abe Y, Chen QH, Yoneyama H, Yamamoto A, Zhang L (2001) L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. J Hypertens 19:421–429
14. Zhou MS, Nishida Y, Chen QH, Kosaka H (1999) Endothelium-derived contracting factor in carotid artery of hypertensive Dahl rats. Hypertension 34:39–43
15. Linder L, Kiowski W, Bühler FR, Lüscher TF (1990) Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 81:1762–1767
16. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323:22–27
17. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA (1993) Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87:1468–1474
18. Félétou M, Vanhoutte PM (2006) Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 26:1215–1225
19. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K (2002) Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 15:326–332
20. Sessa WC (2005) Regulation of endothelial derived nitric oxide in health and disease. Mem Inst Oswaldo Cruz 100:15–18
21. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032–2037
22. Gryglewski RJ, Palmer RM, Moncada S (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320:454–456
23. Mehta JL, Lopez LM, Chen L, Cox OE (1994) Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 74:901–905
24. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK (1992) Oxygen free radicals in essential hypertension. Mol Cell Biochem 111:103–108
25. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A (1998) Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 97:2222–2229
26. Vanhoutte PM, Tang EH (2008) Endothelium-dependent contractions: when a good guy turns bad! J Physiol 586:5295–304
27. Ferder L, Inserra E, Martinez-Maldonado M (2006) Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 8:191–198
28. Zhang H, Schmeisser A, Garlichs CD, Plötze K, Damme U, Mügge A, Daniel WG (1999) Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215–222
29. Dohi Y, Hahn AW, Boulanger CM, Bühler FR, Lüscher TF (1992) Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19:131–137
30. Pollock DM, Keith TL, Highsmith RF (1995) Endothelin receptors and calcium signaling. FASEB J 9:1196–1204
31. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J (2000) Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET(B) receptors. Hypertension 35:732–739
32. Asano H, Shimizu K, Muramatsu M, Iwama Y, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T (1994) Prostaglandin H2 as an endothelium-derived contracting factor modulates endothelin-1-induced contraction. J Hypertens 12:383–390
33. Auch-Schwelk W, Vanhoutte PM (1992) Contractions to endothelin in normotensive and spontaneously hypertensive rats: role of endothelium and prostaglandins. Blood Press 1:45–49
34. Taddei S, Vanhoutte PM (1993) Role of endothelium in endothelin-evoked contractions in the rat aorta. Hypertension 21:9–15
35. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J (2005) Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 11:223–227
36. Hirao A, Kondo K, Takeuchi K, Inui N, Umemura K, Ohashi K, Watanabe H (2008) Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries. Cardiovasc Res 79:161–168
37. Park SJ, Lee JJ, Vanhoutte PM (1999) Endothelin-1 releases endothelium-derived endoperoxides and thromboxane A_2 in porcine coronary arteries with regenerated endothelium. Acta Pharmacol Sin 20:872–878
38. Lüscher TF, Vanhoutte PM (1986) Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8:344–348
39. Gao YJ, Lee RM (2005) Hydrogen peroxide is an endothelium-dependent contracting factor in rat renal artery. Br J Pharmacol 146:1061–1068
40. Nishimura Y, Usui H, Kurahashi K, Suzuki A (1995) Endothelium-dependent contraction induced by acetylcholine in isolated rat renal arteries. Eur J Pharmacol 275:217–221
41. Taddei S, Virdis A, Mattei P, Salvetti A (1993) Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21:929–933
42. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S (2009) Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 157:527–536
43. Tang EH, Leung FP, Huang Y, Feletou M, So KF, Man RY, Vanhoutte PM (2007) Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. Br J Pharmacol 151:15–23
44. Félétou M, Verbeuren TJ, Vanhoutte PM (2009) Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br J Pharmacol 156:563–574
45. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM (1995) Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H_2 in the SHR aorta. Circ Res 76:1003–1010
46. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M (2005) Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol 146:834–845
47. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073
48. Yang D, Félétou M, Levens N, Zhang JN, Vanhoutte PM (2003) A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 41:143–148
49. Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, Vanhoutte PM (2005) Endothelium-dependent contractions occur in the aorta of wild-type and $COX2^{-/-}$ knockout but not $COX1^{-/-}$ knockout mice. J Cardiovasc Pharmacol 46:761–765
50. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M, Huang Y (2009) Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104:228–235

51. Shi Y, Man RY, Vanhoutte PM (2008) Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats. Acta Pharmacol Sin 29:185–192
52. Tang EH, Vanhoutte PM (2008) Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 32:409–418
53. Numaguchi Y, Harada M, Osanai H, Hayashi K, Toki Y, Okumura K, Ito T, Hayakawa T (1999) Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. Cardiovasc Res 41:682–688
54. Gluais P, Paysant J, Badier-Commander C, Verbeuren T, Vanhoutte PM, Félétou M (2006) In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A2 as endothelium-derived contracting factors. Am J Physiol Heart Circ Physiol 291:H2255–H2264
55. Gluais P, Vanhoutte PM, Félétou M (2007) Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta. Eur J Pharmacol 556:107–114
56. Zou MH, Leist M, Ullrich V (1999) Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am J Pathol 154:1359–1365
57. Zou MH, Shi C, Cohen RA (2002) High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51:198–203
58. Bachschmid M, Thurau S, Zou MH, Ullrich V (2003) Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation. FASEB J 17:914–916
59. Dai FX, Skopec J, Diederich A, Diederich D (1992) Prostaglandin H2 and thromboxane A2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension 19:795–798
60. Auch-Schwelk W, Katusic ZS, Vanhoutte PM (1990) Thromboxane A_2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 15:699–703
61. Kato T, Iwama Y, Okumura K, Hashimoto H, Ito T, Satake T (1990) Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 15:475–481
62. Yang D, Félétou M, Boulanger CM, Wu HF, Levens N, Zhang JN, Vanhoutte PM (2002) Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 136:104–110
63. Tang EH, Jensen BL, Skott O, Leung GP, Feletou M, Man RY, Vanhoutte PM (2008) The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rat. Cardiovasc Res 78:130–138
64. Rapoport RM, Williams SP (1996) Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 28:64–75
65. Shi Y, Feletou M, Ku DD, Man RY, Vanhoutte PM (2007) The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol 150:624–632
66. Auch-Schwelk W, Katusic ZS, Vanhoutte PM (1989) Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rat. Hypertension 13:859–864
67. Li J, Li W, Li W, Altura BT, Altura BM (2004) Mechanisms of hydroxyl radical-induced contraction of rat aorta. Eur J Pharmacol 499:171–178
68. Rodriguez-Martinez MA, Garcia-Cohen EC, Baena AB, Gonzalez R, Salaices M, Marin J (1998) Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved. Br J Pharmacol 125:1329–1335
69. Yang Z, Zheng T, Zhang A, Altura BT, Altura BM (1998) Mechanisms of hydrogen peroxide-induced contraction of rat aorta. Eur J Pharmacol 344:169–181
70. Tang EH, Vanhoutte PM (2008) Gap junction inhibitors reduce endothelium-dependent contractions in the aorta of spontaneously hypertensive rats. J Pharmacol Exp Ther 327:148–153
71. Katusic ZS, Vanhoutte PM (1989) Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 257:H33–H37
72. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F (1997) Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 129:111–118
73. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Durán WN, Beuve A (2008) Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 103:606–614
74. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mülsch A, Schulz E, Keaney JF Jr, Stamler JS, Münzel T (2004) Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113:482–489
75. Katusic ZS (2001) Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 281:H981–H986
76. Vásquez-Vivar J (2009) Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 47:1108–1119
77. Gokce N (2004) L-Arginine and hypertension. J Nutr 134:2807S–2811S
78. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, Dagre AG, Stamatelopoulos K, Protogerou A, Stamatelopoulos SF (2002) Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 86:317–323
79. Miller AL (2006) The effects of sustained-release L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals. Altern Med Rev 11:23–29
80. Auch-Schwelk W, Katusić ZS, Vanhoutte PM (1992) Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension 19:442–445
81. Feletou M, Tang EH, Vanhoutte PM (2008) Nitric oxide the gatekeeper of endothelial vasomotor control. Front Biosci 13:4198–4217
82. Tang EH, Feletou M, Huang Y, Man RY, Vanhoutte PM (2005) Acetylcholine and sodium nitroprusside cause long-term inhibition of EDCF-mediated contractions. Am J Physiol Heart Circ Physiol 289:H2434–2440
83. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Félétou M (2004) Nitric oxide and inactivation of the endothelium-dependent contracting factor released by acetylcholine in spontaneously hypertensive rat. J Cardiovasc Pharmacol 43:815–820
84. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94:258–265

85. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A (2002) Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 62:265–284
86. Godfraind T (2005) Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 360:2259–2272
87. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O (2006) The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res 71:478–485
88. Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, Fleming I (2003) Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 59:844–853
89. van Amsterdam FT, Roveri A, Maiorino M, Ratti E, Ursini F (1992) Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic Biol Med 12:183–187
90. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T (2003) Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107:2747–2752
91. Moncada S, Vane JR (1997) The role of prostacyclin in vascular tissue. Fed Proc 38:66–71
92. Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y (2007) The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther 12:98–111
93. Belhassen L, Pelle G, Dubois-Rande J, Adnot S (2003) Improved endothelial function by the thromboxane a_2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41:1198–1204
94. Behm DJ, Ogbonna A, Wu C, Burns-Kurtis CL, Douglas SA (2009) Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328:231–239